INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
NCT01367457 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 243
Last updated 2016-04-27
Summary
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
Conditions
- Carcinoma, Renal Cell
- Lymphoma, Mantle-Cell
Interventions
- OTHER
-
Temsirolimus (Non-Interventional Study)
There is not any intervention in this study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-31
- Primary Completion
- 2015-04-30
- Completion
- 2015-04-30
Countries
- Spain
Study Locations
More Related Trials
-
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
NCT01822886 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
NCT03711578 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
NCT01037478 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
NCT05296070 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00290472 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT02631577 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT01116154 ·Status: TERMINATED ·Phase: PHASE1
-
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00179673 ·Status: COMPLETED ·Phase: PHASE2
-
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00109967 ·Status: COMPLETED ·Phase: PHASE2
-
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
NCT00655668 ·Status: TERMINATED ·Phase: PHASE2
-
Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma
NCT01582776 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Maintenance Lenalidomide in Lymphoma
NCT01575860 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
NCT01534715 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
NCT01646021 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
NCT03557918 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05950165 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
NCT05673967 ·Status: COMPLETED
-
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
NCT06826118 ·Status: RECRUITING ·Phase: PHASE2
-
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
NCT01055314 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico
NCT03161613 ·Status: WITHDRAWN
-
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT05910801 ·Status: RECRUITING ·Phase: PHASE2
-
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714 ·Status: RECRUITING ·Phase: PHASE1/PHASE2